BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial

Phase 2a Masked Trial to Identify the Lowest Effective Concentration of BL1107 for Conjunctival Hyperemia in Patients With Dry Eye Disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07778888

Acronym

BRIGHT

Enrollment

Registered

2026-08-21

Start date

2026-10-01

Completion date

2027-02-01

Last updated

2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Disease

Brief summary

Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.

Interventions

DRUGBL1107

BL1107 topical ocular solution

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented diagnosis of dry eye disease * Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis

Exclusion criteria

* Any active ocular disease * Anticipated wearing of contact lenses during study Additional criteria per protocol

Design outcomes

Primary

Measure	Time frame
Primary Part 1: Proportion of participants with complete resolution in conjunctival hyperemia at 30 minutes, in each evaluated concentration of BL1107.	Assessed at 30 minutes
Primary Part 2: Proportion of participants with complete resolution in conjunctival hyperemia at 8 hours, in each evaluated concentration of BL1107	Assessed at 8 hours

Contacts

CONTACTJohnson Varughese

Johnson.Varughese@bausch.com9089271162

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026